FM19G11

FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions[1][2].

Product Specifications

CAS Number

[329932-55-0]

UNSPSC

12352005

Hazard Statement

H228, H315, H319

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fm19g11.html

Purity

98.39

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC(C1=CC=C(C)C=C1)=O)C2=CC=CC(NC(C3=CC=C([N+]([O-])=O)C=C3[N+]([O-])=O)=O)=C2

Molecular Formula

C23H17N3O8

Molecular Weight

463.40

Precautions

H228, H315, H319

References & Citations

[1]Victoria MM, et, al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem. 2010 Jan 8; 285 (2) : 1333-42.|[2]You CG, et, al. FM19G11 inhibits O 6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Med. 2018 May 15; 7 (7) : 3292-3300.|[3]Ana AA, et, al. FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. Int J Mol Sci. 2018 Jan 9; 19 (1) : 200.